In breast cancer, RLN2 produced by tumor-infiltrating neutrophils (TANs) has been shown to stimulate tumor cell migration by activating the G-CSF-RLN2-MMP-9 axis, leading to increased invasiveness and metastatic potential [17]. Here, RLN2 is linked to breast carcinoma.